Provided are: a genome-edited plant production method by which genome editing can be applied to plants including the family Leguminosae that is difficult to transform, without undergoing processes of tissue culture requiring transformation and time; and a genome-edited plant obtained by said method. The present invention pertains to a genome-edited plant production method and a genome-edited plant obtained by said method, the genome-edited plant production method comprising: providing a cutout in a part of a plant capable of autonomously growing; injecting, to the cutout, an Agrobacterium-containing solution for genome editing; introducing a mutation into the plant without leaving a foreign gene therein; and collecting seeds from the plant, into which the mutation has been introduced, without subjecting the plant to a re-differentiation step, to obtain a genome-edited plant.
According to the present invention, a storage unit stores a depression risk evaluation model for calculating an evaluation value indicating the risk of depression by using a feature amount calculated from a prescribed frequency component obtained by decomposing brain waves by means of time-frequency analysis and having a value that changes in accordance with a change in the frequency of occurrence of a phase reset phenomenon. A feature amount calculation unit calculates the same type of feature amount as the feature amount used in the depression risk evaluation model from a prescribed frequency component obtained by decomposing the measured brain waves of a person-to-be-evaluated by means of time-frequency analysis. An evaluation unit calculates an evaluation value indicating the risk of depression of the person-to-be-evaluated by using the feature amount, which has been calculated by the feature amount calculation unit, as the input to the depression risk evaluation model.
A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
A61B 5/374 - Detecting the frequency distribution of signals, e.g. detecting delta, theta, alpha, beta or gamma waves
3.
ESTABLISHMENT OF THERAPY AND DIAGNOSIS FOR ALLERGIC DISEASES THROUGH CONTROL OF IMMUNOGLOBULIN-BINDING PROTEIN
Kanagawa Institute of Industrial Science and Technology (Japan)
University of Tsukuba (Japan)
Metagen, Inc. (Japan)
Inventor
Fukuda, Shinji
Nakato, Gaku
Obana, Nozomu
Furukawa, Risako
Abstract
Determination of the mechanism of allergy development in which a bacterium of the family Lachnospiraceae, which is an enteric bacterium, including Ruminococcus gnavus is involved and developing a method for preventing or treating allergies by intervening in the mechanism. Since the Ibp protein from a bacterium of the family Lachnospiraceae is involved in development of allergies, allergic reactions occurring in vivo can be prevented by administration or induction of in vivo production of a substance that binds to the Ibp protein.
The present description discloses: a (ω-terminal modified) poly(ethylene glycol)-b-poly([R, S]-β-hydroxybutyrate) (PEG-b-PBHB) copolymer; nano-sized polymeric micelles or nanoparticles, which are formed from the copolymer and are capable of controlled release or sustained release of a low molecular weight β-hydroxybutyric acid in vivo; and production or preparation methods of these products, and a pharmaceutical use of the nanoparticles. Since the nanoparticles are capable of controlled release or sustained release of β-hydroxybutyric acid in vivo, physiological activity originally possessed by β-hydroxybutyric acid can be exhibited in vivo.
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61P 25/00 - Drugs for disorders of the nervous system
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
C08J 3/09 - Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in organic liquids
The present invention comprises: a brain wave processing unit that acquires the amplitude and phase, for each of a prescribed plurality of frequency bands, from training brain wave data measured from one mammal living body, and executes a complexity analysis process comprising entropy analysis for each of the acquired amplitudes and phases of the frequency bands; and a machine learning unit that uses the result of the complexity analysis process and label data of a sleep/wakefulness stage corresponding to the training brain wave data so as to execute a machine learning process of a machine learning model for determining the sleep/wakefulness stage.
A prodrug of an anticancer drug is used in combination therapy with radiotherapy. In the chemical formula (1), a moiety in which R1 and R2 bond to an N atom is a part of an anticancer drug having an amino group or an imino group with the amino group or the imino group removed, and the anticancer drug is selected from the group consisting of gemcitabine, niraparib, crizotinib, tabrafenib, vemurafenib, entinostat, cobimetinib, and palbociclib, ribociclib. Thereby, the side effects of the treatment, including radiotherapy, for malignant tumors are reduced or the treatment effect is enhanced.
A prodrug of an anticancer drug is used in combination therapy with radiotherapy. In the chemical formula (1), a moiety in which R1 and R2 bond to an N atom is a part of an anticancer drug having an amino group or an imino group with the amino group or the imino group removed, and the anticancer drug is selected from the group consisting of gemcitabine, niraparib, crizotinib, tabrafenib, vemurafenib, entinostat, cobimetinib, and palbociclib, ribociclib. Thereby, the side effects of the treatment, including radiotherapy, for malignant tumors are reduced or the treatment effect is enhanced.
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Japan)
UNIVERSITY OF TSUKUBA (Japan)
TAIYO SERVICE INC. (Japan)
Inventor
Iwata, Yasushi
Matsui, Hirofumi
Suzuki, Iwane
Suzuki, Yuji
Tomita, Kanako
Yang, Tianjing
Ikeda, Takafumi
Kurokawa, Hiromi
Abstract
Provided is an anticancer agent containing a substance that contains nitrogen-15 and that specifically accumulates in a cancer cell. Also provided is a method for killing a cancer cell in vitro, including accumulating nitrogen-15 in a cancer cell in vitro and irradiating the cancer cell with a proton beam in vitro. Additionally provided is a cancer treatment method including causing an accumulation of the nitrogen-15 in a cancer cell in a human or a nonhuman animal and irradiating the human or the nonhuman animal with a proton beam.
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A therapeutic device estimates an outer shape of a target using an identifier that performed learning based on a first image capturing in vivo information of a subject, a second image showing the target in vivo, and a third image capturing the same subject using a different device from that used to capture the first image. In a configuration in which the shape of a target object site is learned using a DRR image processed from a CT image, the therapeutic device can accurately estimate the shape of the target object site.
An information processing device includes a reception unit that receives a plurality of OCT images captured under different image-capturing conditions and represented by complex signals, an image processing unit that performs digital refocusing by complex signal processing or digital aberration correction by the complex signal processing on each of the plurality of OCT images received by the reception unit, and a synthesis unit that synthesizes the plurality of OCT images on which the image processing unit has performed the digital refocusing by the complex signal processing or the digital aberration correction by the complex signal processing.
An intraocular illumination device includes a fiber that guides light from a light source, and a holder that is disposed between an objective lens of a microscope and an eye during eye surgery or examination and supports a tip portion of the fiber. The tip portion of the fiber is provided with a reflecting portion that reflects the light guided through the fiber toward an inside of the eye.
Provided is a gas supply device for short-time respiration that does not require skill and can make parasympathetic nerves dominant in a short time in order to suppress chronic stress without causing mood inhibition. A gas supply device 1 for short-time respiration comprises: a normal-pressure low-oxygen gas supply device 11 capable of supplying a normal-pressure gas having a predetermined oxygen concentration that does not cause mood inhibition when inhaled by a user for breathing; an oxygen saturation level detection device 32 capable of detecting an oxygen saturation level in the user; and a control device 20 which determines whether or not the oxygen saturation level in the user detected by the oxygen saturation level detection device 32 is equal to or greater than a predetermined value, and which, if it is determined that the oxygen saturation level in the user is less than the predetermined value, performs control to stop the normal-pressure low-oxygen gas supply device from producing and outputting the normal-pressure gas having the predetermined oxygen concentration to a gas output unit.
A61M 16/10 - Preparation of respiratory gases or vapours
A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
A63B 26/00 - Exercising apparatus not covered by groups
12.
ELECTRON SPIN RESONANCE DEVICE AND DETERIORATION EVALUATION METHOD
An electron spin resonance device includes a microwave oscillator, a magnet, a modulation coil, and a cavity resonator having an opening. A microwave generated in the microwave oscillator resonates in the cavity resonator and is emitted from the opening toward a measurement target located outside the opening. The magnet applies a magnetic field toward an irradiation surface of the measurement target, the irradiation surface being irradiated with the microwave. The modulation coil modulates an intensity of the magnetic field or a frequency of the microwave applied toward the irradiation surface of the measurement target irradiated with the microwave.
G01R 33/60 - Arrangements or instruments for measuring magnetic variables involving magnetic resonance using electron paramagnetic resonance
G01N 24/10 - Investigating or analysing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using electron paramagnetic resonance
G01R 33/36 - Electrical details, e.g. matching or coupling of the coil to the receiver
13.
SEMICONDUCTOR APPARATUS AND METHOD FOR MANUFACTURING SEMICONDUCTOR APPARATUS
This semiconductor apparatus has a base film and a semiconductor film formed on the base film, wherein the base film comprises a polyimide obtained by condensation polymerization of an aromatic diamine and an aromatic tetracarboxylic acid anhydride and has a tensile elasticity in the machine direction of 7 GPa or more, and the semiconductor film is polycrystalline and comprises crystal particles having an average particle size of 1 μm or more.
As a method for manufacturing a carbon nanotube assembled wire, that is capable of manufacturing the carbon nanotube assembled wire in a tubular carbon nanotube synthesis furnace efficiently, an adhesion suppressing gas stream is generated from an adhesion suppressing gas discharge port located between a second end of the carbon nanotube synthesis furnace and an end of a heater closer to the second end, the adhesion suppressing gas stream flowing between an internal wall of the carbon nanotube synthesis furnace and an external wall of a first channel, in which carbon nanotubes are oriented to form the carbon nanotube assembled wire, in a direction from the second end toward a first end to suppress adhesion of a plurality of carbon nanotubes to the internal wall of the carbon nanotube synthesis furnace.
B01J 8/18 - Chemical or physical processes in general, conducted in the presence of fluids and solid particlesApparatus for such processes with fluidised particles
C01B 32/162 - Preparation characterised by catalysts
D01F 9/127 - Carbon filamentsApparatus specially adapted for the manufacture thereof by thermal decomposition of hydrocarbon gases or vapours
RADIATION SHIELDING MATERIAL, SHIELDING MATERIAL FOR SEMICONDUCTOR DEVICE, PACKAGE FOR SEMICONDUCTOR DEVICE, SHIELDING MATERIAL FOR NUCLEAR REACTOR, NUCLEAR REACTOR CONTAINMENT VESSEL, NUCLEAR REACTOR BUILDING, SHIELDING MATERIAL FOR NUCLEAR FUSION REACTOR, NUCLEAR FUSION REACTOR, AND NUCLEAR FUSION REACTOR BUILDING
G21F 1/10 - Organic substancesDispersions in organic carriers
G21F 3/00 - Shielding characterised by its physical form, e.g. granules, or shape of the material
H05K 9/00 - Screening of apparatus or components against electric or magnetic fields
16.
NEUTRON RADIATION SHIELDING MATERIAL, SHIELDING MATERIAL FOR SEMICONDUCTOR DEVICE, PACKAGE FOR SEMICONDUCTOR DEVICE, SHIELDING MATERIAL FOR NUCLEAR REACTOR, NUCLEAR REACTOR CONTAINMENT VESSEL, NUCLEAR REACTOR BUILDING, SHIELDING MATERIAL FOR NUCLEAR FUSION REACTOR, NUCLEAR FUSION REACTOR, AND NUCLEAR FUSION REACTOR BUILDING
G21F 1/10 - Organic substancesDispersions in organic carriers
G21F 3/00 - Shielding characterised by its physical form, e.g. granules, or shape of the material
H05K 9/00 - Screening of apparatus or components against electric or magnetic fields
17.
NEUTRON RADIATION SHIELDING MATERIAL, SHIELDING MATERIAL FOR SEMICONDUCTOR DEVICE, PACKAGE FOR SEMICONDUCTOR DEVICE, SHIELDING MATERIAL FOR NUCLEAR REACTOR, NUCLEAR REACTOR CONTAINMENT VESSEL, NUCLEAR REACTOR BUILDING, SHIELDING MATERIAL FOR NUCLEAR FUSION REACTOR, NUCLEAR FUSION REACTOR, AND NUCLEAR FUSION REACTOR BUILDING
This neutron radiation shielding material for blocking neutron radiation contains a boride, and the average particle size of said boride is 500 μm or less.
G21F 1/10 - Organic substancesDispersions in organic carriers
G21F 3/00 - Shielding characterised by its physical form, e.g. granules, or shape of the material
H05K 9/00 - Screening of apparatus or components against electric or magnetic fields
18.
NEUTRON RADIATION SHIELDING MATERIAL, SHIELDING MATERIAL FOR SEMICONDUCTOR DEVICE, PACKAGE FOR SEMICONDUCTOR DEVICE, SHIELDING MATERIAL FOR NUCLEAR REACTOR, NUCLEAR REACTOR CONTAINMENT VESSEL, NUCLEAR REACTOR BUILDING, SHIELDING MATERIAL FOR NUCLEAR FUSION REACTOR, NUCLEAR FUSION REACTOR, AND NUCLEAR FUSION REACTOR BUILDING
This neutron radiation shielding material for blocking neutron radiation includes a resin-containing layer and a borohydride-containing layer, wherein one of the resin-containing layer and the borohydride-containing layer is disposed on a side exposed to the radiation source of neutron radiation.
G21F 1/10 - Organic substancesDispersions in organic carriers
G21F 3/00 - Shielding characterised by its physical form, e.g. granules, or shape of the material
H05K 9/00 - Screening of apparatus or components against electric or magnetic fields
19.
NEUTRON RADIATION SHIELDING MATERIAL, SHIELDING MATERIAL FOR SEMICONDUCTOR DEVICE, PACKAGE FOR SEMICONDUCTOR DEVICE, SHIELDING MATERIAL FOR NUCLEAR REACTOR, NUCLEAR REACTOR CONTAINMENT VESSEL, NUCLEAR REACTOR BUILDING, SHIELDING MATERIAL FOR NUCLEAR FUSION REACTOR, NUCLEAR FUSION REACTOR, AND NUCLEAR FUSION REACTOR BUILDING
A neutron radiation shielding material for blocking neutron radiation, wherein the attenuation rate of neutron radiation of 0.5 eV is 1e-2 or less when the thickness of the neutron radiation shielding material is 1 cm.
An information processing device according to an embodiment includes a learning unit that performs learning on a machine learning model having one or more non-polarization OCT images that are OCT images without polarization information as inputs and a pseudo polarization OCT image corresponding to a polarization OCT image that is an OCT image with polarization information as output; and a storage unit that stores a learning result of the learning unit.
A method for manufacturing a carbon nanotube assembled wire includes: a first step of supplying a carbon-containing gas at one, first end of a tubular carbon nanotube synthesis furnace to grow a carbon nanotube from each of a plurality of catalyst particles suspended in the carbon nanotube synthesis furnace to synthesize a plurality of carbon nanotubes; a second step of orienting the plurality of carbon nanotubes in a longitudinal direction of the carbon nanotubes in a first channel provided in the carbon nanotube synthesis furnace, and thus assembling them together, to form a carbon nanotube assembled wire; and a third step of collecting the carbon nanotube assembled wire using a collecting gas stream flowing from a second end of the carbon nanotube synthesis furnace opposite to the first end in a direction away from the carbon nanotube synthesis furnace.
[Problem] To provide an antibody that binds with at least one of human CD300A-R and human CD300A-Q, does not bind with human CD300C, and inhibits binding between human CD300A and a ligand thereof. [Solution] Provided is an anti-human CD300A monoclonal antibody, or an antigen-binding fragment thereof, which satisfies requirement (i), (ii) or (iii) described in the description.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
The present invention provides an information processing device capable of setting meaningful upper and lower limits even in high-resolution data to perform sufficient verification. Provided is an information processing device (200) comprising: a smooth distance estimation means (203) that inputs an error rate and estimates a smoothed distance between a query image and a candidate image; and a rank range estimation means (204) that uses the smoothed distance to estimate a rank range. The information processing device inputs a different query image for the candidate image or a different candidate image for the query image. The information processing device comprises: a distance upper and lower limit estimation means (403) that estimates upper and lower limits of the distance between the query image and the candidate image; and a sufficient condition evaluation means (404) that evaluates whether the upper and lower limits of the distance are within the estimated rank range.
G06F 21/57 - Certifying or maintaining trusted computer platforms, e.g. secure boots or power-downs, version controls, system software checks, secure updates or assessing vulnerabilities
24.
ORGANIC HYDRIDE PRODUCTION DEVICE AND ORGANIC HYDRIDE PRODUCTION METHOD
This organic hydride production device 2 comprises, as an anode catalyst 11, an anode electrode 10 having a high entropy alloy containing a base metal element, a cathode electrode 8, and an electrolyte membrane 12 positioned between the anode electrode 10 and the cathode electrode 8. The anode electrode 10 oxidizes water or hydroxide ions. The cathode electrode 8 electrochemically reduces a hydride to generate an organic hydride.
C25B 9/23 - Cells comprising dimensionally-stable non-movable electrodesAssemblies of constructional parts thereof with diaphragms comprising ion-exchange membranes in or on which electrode material is embedded
C25B 11/052 - Electrodes comprising one or more electrocatalytic coatings on a substrate
A MnBi-based magnet according to an embodiment includes crystal grains of (MnBi)aMb composition including a manganese element, a bismuth and a M element, wherein the M element is contained an amount of more than 0 at % and less than or equal to 10 at % when at % for all atoms of (MnBi)aMb is 100 at %, and the M element includes a chromium element, a germanium element, or a tellurium element.
Provided are a hydrogen boride-containing composition, a hydrogen generation system, and a fuel cell system that achieve further performance improvement of a hydrogen supply source with a hydrogen boride-containing sheet. The hydrogen boride-containing composition contains a hydrogen boride-containing sheet having a two-dimensional network consisting of (BH)n(n≥4, where n is an integer) and an electron donor. At least a portion of the electron donor is supported on the hydrogen boride-containing sheet, electrons of the electron donor are supplied to the hydrogen boride-containing sheet by external stimulus, and hydrogen is generated from the hydrogen boride-containing sheet into which the electrons are injected.
H01M 8/0606 - Combination of fuel cells with means for production of reactants or for treatment of residues with means for production of gaseous reactants
C01B 3/04 - Production of hydrogen or of gaseous mixtures containing hydrogen by decomposition of inorganic compounds, e.g. ammonia
C01B 6/00 - Hydrides of metalsMonoborane or diboraneAddition complexes thereof
27.
METHOD FOR INTRODUCING SUBSTANCE INTO GENERATIVE CELLS
NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (Japan)
UNIVERSITY OF TSUKUBA (Japan)
Inventor
Minagawa Sachi
Tanaka Saeko
Kurihara Mizuta Yoko
Wada Yusaku
Ezura Hiroshi
Kang Seung Won
Akase Kosuke
Worarad Kanjana
Mitalo Oscar Witere
Abstract
This method for introducing a substance into generative cells comprises a step for combining a cell membrane-penetrating peptide containing an amphipathic amino acid sequence with the substance and introducing the resultant into pollen.
The present invention provides a plasma processing device capable of controlling the amount of water vapor added to an operating gas and the irradiation distance and widely controlling the wettability of the surface of a resin material that is the object. This plasma processing device performs plasma processing by irradiating an object (80) with atmospheric plasma (99). The plasma processing device comprises: a bubble generation container (64) for adding water vapor to an operating gas; a dew point meter (31) for adjusting the amount of water vapor added to the operating gas; a plasma generation unit (90) for generating atmospheric pressure plasma by applying high-frequency power to the operating gas in which the amount of water vapor added has been adjusted; a plasma delivery unit (91) for delivering the atmospheric pressure plasma toward the object; and an irradiation distance adjustment unit (400) for adjusting the plasma irradiation distance (L1) from the plasma delivery unit to the object.
A method for manufacturing a carbon nanotube assembled wire includes: a first step of supplying a carbon-containing gas to a plurality of catalyst particles in a suspended state in a tubular carbon nanotube synthesis furnace to grow a carbon nanotube from each of the plurality of catalyst particles to obtain a plurality of carbon nanotubes; and a second step of assembling the plurality of carbon nanotubes together to obtain a plurality of carbon nanotube assembled wires.
The purpose of this invention is to avoid accidental exposure of an infant patient in an infant incubator to a volatile substance. A purification device (2) is installed to an infant incubator (1) provided with a housing chamber (101), wherein the temperature and humidity inside the housing chamber (101) can be adjusted for housing an infant patient (X), and the purification device (2) purifies air including a volatile substance vaporized during medical practice with the volatile substance for an infant patient housed in the housing chamber (101). The purification device (2) comprises: a removal unit (3) for removing a volatile substance from air; a casing (4) capable of holding at least the removal unit (3); and a fixing unit (5) for fixing the casing (4) outside the infant incubator (1).
B01D 53/04 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography with stationary adsorbents
31.
INCUBATOR CONTROL DEVICE, INCUBATOR, VENTILATION DEVICE, AND INCUBATOR CONTROL METHOD
The present invention provides an incubator control device capable of adjusting, to appropriate ranges, the temperature and humidity in the interior of an accommodation chamber capable of accommodating an infant, said incubator control device being provided to an incubator. An incubator control device (200) is provided to an incubator (1) and comprises: a ventilation control unit (203) that controls at least one from among the amount of air supplied from the outside to the inside of an accommodation chamber (101) capable of accommodating an infant and the amount of air discharged from the inside to the outside of said accommodation chamber; and a temperature/humidity control unit (202) that controls the temperature and humidity in the interior of the accommodation chamber. The temperature/humidity control unit controls the ventilation control unit on the basis of information about the chamber interior temperature/humidity, which is the temperature and humidity in the interior of the accommodation chamber.
Provided is a valproic acid derivative for improving disadvantages or defects accompanying when valproic acid itself or the like is used as a medicine. Provided is a block copolymer which is a polymerized product of valproic acid and comprises a poly(ethylene glycol) segment and a poly(vinyl valproate) segment.
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
C08F 293/00 - Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Japan)
Inventor
Kawanishi, Kunio
Kuno, Atsushi
Okatani, Chiaki
Sato, Takashi
Sakaue, Hiroaki
Kaji, Hiroyuki
Abstract
Provided is a biomarker capable of specifically detecting renal cell cancer. Based on our finding that sialylation (sialic acid modification) is accentuated in the case of acquired cystic kidney disease associated renal cell carcinoma (ACD-RCC) compared to clear cell renal cell carcinoma (cc-RCC) from techniques in which cancer-specific regions are collected under a microscope from histopathology samples and diverse omics analyses such as lectin arrays and RNAseq, we have identified, by glycoproteomics that includes mass spectrometry, a glycoprotein group having a sugar chain structure containing a specific glycosylation, in particular, a sialylation, among protein groups from cancer tissue of renal cell cancer, and this glycoprotein group is provided as a new biomarker specific for renal cell cancer.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
34.
STRUCTURAL BODY INCLUDING BORON, HYDROGEN, AND OXYGEN, AND METHOD FOR PRODUCING SAME
The object of the present invention is to provide an excellent method for storing and transporting hydrogen.
The object of the present invention is to provide an excellent method for storing and transporting hydrogen.
The object can be solved by a structure comprising boron, hydrogen, and oxygen, that has B—H—B bonds, B—H bonds, and B—OH bonds, and in the measurement of FT-IR spectra, the following formulas are satisfied: (1) 0.80≤a/c≤0.96, and (2) 0.95≤b/c≤1.12, wherein when the baseline is defined as 100%, a is the transmittance at 1400 cm−1 in the FT-IR spectrum, b is the transmittance at 2500 cm−1 in the FT-IR spectrum, and c is the transmittance at 3200 cm−1 in the FT-IR spectrum.
This carbon nanotube assembly wire comprises a plurality of carbon nanotubes, wherein: the plurality of carbon nanotubes include a plurality of nitrogen-doped single-walled carbon nanotubes; the nitrogen content of the carbon nanotube assembly wire is 0.5 atom% to 6 atom% inclusive; and the content of graphitic nitrogen of the carbon nanotube assembly wire is 0.4 atom% to 3.5 atom% inclusive.
D01F 9/10 - Man-made filaments or the like of other substancesManufacture thereofApparatus specially adapted for the manufacture of carbon filaments of inorganic material by decomposition of organic substances
According to the present invention, this depression level estimation device comprises a storage unit, a feature amount calculation unit, and an estimation unit. The storage unit stores a depression level estimation model. A depression level estimation model represents a correlation between a feature amount calculated from frequency components in a prescribed frequency range obtained by decomposing brainwaves of a measurement subject through time-frequency analysis and the depression level that represents the level of a depressed mood of the measurement subject. The feature amount calculation unit calculates the feature amount from the frequency components obtained by decomposing the measured brainwaves of the measurement subject through the time-frequency analysis. The estimation unit uses the depression level estimation model to estimate the depression level corresponding to the feature amount calculated by the feature amount calculation unit. As the feature amount, a variate, which varies according to the occurrence frequency of phase resetting, may be used.
A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
A61B 5/374 - Detecting the frequency distribution of signals, e.g. detecting delta, theta, alpha, beta or gamma waves
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
A cold sensation presentation device includes: a cold stimulus section that contactlessly gives a cold stimulus to a skin; a warm stimulus section that contactlessly gives a warm stimulus to a skin; and a control unit that presents a cold sensation by causing a temporal change in the intensity of the cold stimulus in a cold stimulus state where the intensity of the warm stimulus is relatively small and a temporal change in the intensity of the warm stimulus in a warm stimulus state where the intensity of the warm stimulus is relatively large to be different from each other, and repeating the cold stimulus state and the warm stimulus state in a state of keeping the intensity of the cold stimulus constant.
Provided is a tissue-marking agent that improves the dispersion stability of fine particles labelled with a fluorescent dye in an aqueous medium. The present invention involves dispersing fine particles labelled with a fluorescent dye in an aqueous medium containing a water-soluble viscous substance.
This conversion circuit converts an input current into an output voltage, and comprises: a first terminal that is an input section for the input voltage; a second terminal that is a ground; a third terminal that is an output section for the output voltage, and is for supplying a power source voltage via a power source supply resistor; a first resistor that is connected to the first terminal at one end and is connected to the third terminal and the other end; and a regulator that detects the difference between the voltage of the first terminal and a preset reference voltage, and when the voltage of the first terminal is higher than the reference voltage, performs control so as to adjust, in accordance with said difference, the quantity of current flowing from the third terminal to the second terminal, lower the voltage of the third terminal, and maintain the voltage of the first terminal at the reference voltage, wherein the gain of the conversion circuit is determined by the first resistor.
H03F 3/34 - DC amplifiers in which all stages are DC-coupled
G05F 1/613 - Regulating voltage or current wherein the variable actually regulated by the final control device is DC using semiconductor devices in parallel with the load as final control devices
Provided is a gel material for ophthalmic treatment useful as a synthetic vitreous body which is a novel intraocular tamponade material having a low swelling pressure, an appropriate elastic force, and no toxicity to ocular tissues, specifically, to retinas, and which is capable of stably maintaining a long-term stable tamponade effect. A gel material for ophthalmic treatment including a hydrogel in which a gel precursor cluster crosslinks to form a three-dimensional network. The gel precursor cluster has a structure with crosslinked monomer units or crosslinked polymer units present at concentrations less than a critical gelation concentration, and the gel precursor cluster has a relationship of G′
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
This production device for a carbon nanotube wire comprises a first tube, a second tube, a first supply part, and a second supply part. The first tube has a first inner circumferential surface and an outer circumferential surface. The outer circumferential surface surrounds the first inner circumferential surface. The second tube has a second inner circumferential surface. The second inner circumferential surface surrounds the outer circumferential surface. The second inner circumferential surface extends along the outer circumferential surface. The first supply part supplies a raw material for carbon nanotubes and a chlorosulfonic acid into the first tube. The second supply part supplies a coagulant liquid into the second tube. The first tube has a first end. The first end lies inside the second tube.
This film formation method comprises step a) and step b). Step a) forms a metal oxide film. Step b) dopes the metal oxide film with a dopant, the dopant being such that, when the metal oxide film is doped therewith, an energy difference obtained by subtracting an energy by which the crystal structure of the metal oxide film becomes monoclinic from an energy by which the crystal structure becomes tetragonal is lower than an energy difference in the metal oxide film in an undoped state.
H01L 21/31 - Treatment of semiconductor bodies using processes or apparatus not provided for in groups to form insulating layers thereon, e.g. for masking or by using photolithographic techniquesAfter-treatment of these layersSelection of materials for these layers
H01L 21/425 - Bombardment with radiation with high-energy radiation producing ion implantation
43.
METHOD AND DEVICE FOR INDUCING HYPOMETABOLIC STATE IN SUBJECT WITH DISEASE
The present invention provides a method for inducing a hibernation-like state and an apparatus therefor. According to the present invention, provided is a method for decreasing a theoretical setpoint temperature of body temperature and a feedback gain of heat generation in a subject or a method for inducing a hibernation-like state in a subject, the method being a chemical and/or physical method including providing an excitatory stimulus to a pyroglutamylated RFamide peptide (QRFP)-producing neuron. According to the present invention, an apparatus used to practice this method is also provided.
The purpose of the present invention is to provide: a nucleic acid for gene expression uses, which can amplify a conditional gene expression vector stably, can be used in a gene expression analysis in a wide variety of organism species and cell species, can be predicted with respect to the expression amount thereof, and can be used in a gene expression vector having broad utility and capable of being used for an analysis at an organism individual level; and a gene expression vector, a method for producing the gene expression vector, and a gene expression method, in each of which the nucleic acid is used. Provided are: a nucleic acid for gene expression uses, which is intended to be use in a gene expression vector containing a recombinant enzyme expression gene, is introduced to the upstream of the recombinant enzyme expression gene, and comprises a sequence in which TA is repeated at least five times; and a gene expression vector, a method for producing the gene expression vector, and a gene expression method, in each of which the nucleic acid is used.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A01K 67/027 - New or modified breeds of vertebrates
C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
45.
BODY TEMPERATURE LOWERING AGENT, BODY TEMPERATURE ELEVATION SUPPRESSOR, FOOD COMPOSITION FOR LOWERING BODY TEMPERATURE,AND FOOD COMPOSITION FOR SUPPRESSING BODY TEMPERATURE ELEVATION
A body temperature lowering agent, a body temperature elevation suppressor, a food composition for lowering body temperature, and a food composition for suppressing body temperature elevation containing at least one substance selected from the group consisting of orotic acid, a derivative thereof, and a salt of the orotic acid or the derivative as an active ingredient.
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Japan)
DAICO MFG CO., LTD. (Japan)
Inventor
Kumada, Hiroaki
Kitamura, Naoyuki
Nakamura, Tetsuyuki
Ikeda, Takeshi
Abstract
The purpose is to prevent the irradiation beam from leaking between the beam irradiation port of the radiation therapy device and the patient affected area that is the target of the emitted irradiation beam, a radiation shielding jig comprising a tare filled with shielding material particles; the tare is made of a resin fabric and has a hollow three-dimensional shape with a radiation pathway portion, the shielding material particles comprising a mixture of sintered particles having a predetermined particle diameter with radiation shielding performance and resin particles having a predetermined particle diameter.
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Japan)
DAICO MFG CO., LTD. (Japan)
Inventor
Kumada, Hiroaki
Kitamura, Naoyuki
Nakamura, Tetsuyuki
Ikeda, Takeshi
Abstract
The purpose is to prevent the irradiation beam from leaking between the beam irradiation port of the radiation therapy device and the patient affected area that is the target of the emitted irradiation beam, a radiation shielding jig comprising a tare filled with shielding material particles; the tare is made of a resin fabric and has a hollow three-dimensional shape with a radiation pathway portion, the shielding material particles comprising a mixture of sintered particles having a predetermined particle diameter with radiation shielding performance and resin particles having a predetermined particle diameter.
48.
MICROBIAL STRAIN, PROTEIN, AND METHOD FOR PRODUCING GALLIC ACID USING MICROBIAL STRAIN OR PROTEIN
The purpose of the present technology is to provide: a protein that has a protocatechuic acid 5-position oxidizing activity and can efficiently generate gallic acid from protocatechuic acid; and a microbial strain that expresses said protein. In the present invention, the use of a protocatechuic acid 5-position oxidizing enzyme derived from Comamonas microbes or a protein having at least 70% identity with the amino acid sequence of said protocatechuic acid 5-position oxidizing enzyme allows efficient production of gallic acid from protocatechuic acid. Gallic acid can be produced from protocatechuic acid as a result of fermentation using a microbial strain into which a gene that codes for said enzyme has been introduced.
The purpose of the present invention is to provide a novel nucleic acid construct that induces antibody production. The present invention provides a nucleic acid construct that induces antibody production against a target protein, the nucleic acid construct including a polynucleotide that codes for at least two types of T cell epitopes and a polynucleotide that codes for one or more types of B cell epitopes for the target protein. The present invention makes it possible to powerfully induce antibodies against a target protein within the body of a subject, making it possible not only to induce antibody production against exogenous antigens such as bacteria and viruses but also to induce antibody production against proteins produced within the body of the self.
This method is for producing a microfibrillated cellulose molded article formed of a microfibrillated cellulose and a phenolic resin. The method for producing a microfibrillated cellulose molded article comprises: a step for preparing a first preliminary molded sheet formed of a microfibrillated cellulose and 0-10 mass% of water; a step for obtaining a second preliminary molded sheet by exposing the first preliminary molded sheet to water for at least one hour to swell the sheet; a step for obtaining a third preliminary molded sheet by replacing the water contained in the second preliminary molded sheet with a solution containing a phenolic resin having a weight-average molecular weight of at most 1000; a step for drying the obtained third preliminary molded sheet; and a step for thermally pressing the dried third preliminary molded sheet by applying a pressure of 1-10 MPa to the sheet in the thickness direction at a temperature of 120-200°C.
D21H 19/24 - Coatings without pigments applied in a form other than the aqueous solution defined in group comprising macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
D21H 11/18 - Highly hydrated, swollen or fibrillatable fibres
51.
APPARATUS USED TO DETECT OR STIMULATE ACTIVITY OF NERVE TISSUE
This apparatus (1) comprises at least one intravascular device (10), (20) that is disposed in a blood vessel of an organism and that is equipped with at least one electrode (11), (12), (21), (22) for detecting or stimulating the activity of nerve tissue positioned outside the blood vessel nearby, the electrodes (11), (12), (21), (22) being provided on a wire member.
The purpose of the present invention is to provide: a composition which is capable of efficiently releasing hydrogen; and a hydrogen release method. The above are achieved by means of a composition which contains a borohydride sheet and a carrier at a volume ratio of 1:0.1 to 100 so that the transmittance of ultraviolet light is more than 0% but less than 100%.
A secondary battery of the present disclosure includes a positive electrode, an electrolyte layer, a negative electrode current collector, and metallic lithium as a negative electrode active material that is deposited between the electrolyte layer and the negative electrode current collector by charging, an intermediate layer is present between the electrolyte layer and the negative electrode current collector, and the intermediate layer contains hydrogen boride.
The purpose of the present invention is to provide a pharmaceutical composition and the like for treating or preventing inflammation caused by Acanthamoeba. Specifically provided are a pharmaceutical composition for treating or preventing inflammation caused by Acanthamoeba that contains a composite formed by joining lysozyme and chitosan, an antiprotozoal composition that contains a composite formed by joining lysozyme and chitosan, an anti-attachment agent for Acanthamoeba that contains a composite formed by joining lysozyme and chitosan, and the like.
A61K 47/61 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
The present invention provides a method for producing natural polymer microspheres, the method including: adding a solution containing a natural polymer (e.g., an aqueous fibroin solution) to an organic solvent, the organic solvent having a surfactant dissolved therein, and homogenizing the resulting mixed solution to generate a natural polymer colloidal suspension; and adding the natural polymer colloidal suspension to an alcohol having 3 or more carbon atoms to form natural polymer microspheres.
A contact lens-shaped intraocular lighting device comprising: a contact lens including a dome-shaped first region that is provided in a central portion and through which light is transmitted, a ring-shaped second region that extends outward in a radial direction from an outer peripheral portion of the first region, and a ring-shaped third region that extends outward in the radial direction from an outer peripheral portion of the second region and is provided to be in contact with the sclera; and a lighting unit that is provided in the second region of the contact lens, adjusts refraction or diffusion of light provided from a light source, and emits the light into the eye.
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Japan)
UNIVERSITY OF TSUKUBA (Japan)
Inventor
Nosato, Hirokazu
Kochi, Yuta
Sakanashi, Hidenori
Murakawa, Masahiro
Ikeda, Atsushi
Abstract
An endoscopic diagnosis support method whereby an examined area and an unexamined area can be clearly discriminated. After a preparatory step of an observation canvas is performed in advance, a frame marking step, a key point calculation step, a preceding and following frame displacement amount calculation step, a preceding and following frame marking step are executed to thereby perform observation recording. In an image diagnosis support step IDS, support is performed such that the existence of a lesion is diagnosed in an organ on the basis of a plurality of position data marked with respect to a plurality of frames in the observation canvas data and an endoscopic image in the plural frames.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G06V 10/44 - Local feature extraction by analysis of parts of the pattern, e.g. by detecting edges, contours, loops, corners, strokes or intersectionsConnectivity analysis, e.g. of connected components
G06T 7/73 - Determining position or orientation of objects or cameras using feature-based methods
A61B 1/05 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor combined with photographic or television appliances characterised by the image sensor, e.g. camera, being in the distal end portion
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
58.
ORGAN DEFORMATION ESTIMATION DEVICE, TREATMENT DEVICE, TREATMENT ASSISTANCE DEVICE, ORGAN DEFORMATION ESTIMATION METHOD, AND PROGRAM
This organ deformation estimation device is provided with: a three-dimensional model acquisition unit which acquires a three-dimensional model that shows the shape of an organ, the three-dimensional model being generated on the basis of a three-dimensional image of the organ which has been captured previously before the implementation of a treatment; a captured image acquisition unit which acquires a captured image that is an image of the inside of the organ which has been captured during the process of the treatment; a partial image extraction unit which extracts a partial image from the three-dimensional image; an alignment unit which performs the alignment of the captured image with the partial image; a target position calculation unit which calculates a target position on the basis of the result of the alignment; and a displacement estimation unit which estimates the deformation of the organ during the process of the treatment by deforming the three-dimensional model on the basis of a three-dimensional simulation in such a manner that the position of a part corresponding to the inside among parts constituting the three-dimensional model is displaced to the target position.
A non-transitory computer-readable recording medium has stored therein a program that causes a computer to execute a process, the process including acquiring movie data including a plurality of consecutive frames calculating first likelihood of a class of the movie data by inputting the acquired movie data to a trained model, calculating an optical flow indicating movement of an area included in the movie data, based on the movie data generating occluded movie data by setting an occluded area in each of the frames included in the movie data, based on the optical flow, calculating second likelihood of a class of the occluded movie data by inputting the occluded movie data to the model identifying an area that affects identification of the class among areas in the movie data, based on the first likelihood and the second likelihood and displaying the identified area that affects identification of the class.
The present invention provides an information processing method, an information processing system, and a computer program. According to the present invention, a computer executes processing that: acquires respective first intermediate representations from a plurality of devices, the first intermediate representations being obtained by applying an intermediate representation conversion function to first data used individually at the devices; acquires respective second intermediate representations from the plurality of devices, the second intermediate representations being obtained by applying the intermediate representation conversion function to second data used in common at the devices; adjusts a parameter for an integrated representation conversion function to minimize the difference in integrated representations obtained by applying the integrated representation conversion function to each of the respective second intermediate representations acquired from the devices; and, on the basis of each of the respective first intermediate representations acquired from the devices and the integrated representation conversion function after adjustment of the parameter, derives a device difference correction function for correcting the device difference between the plurality of devices.
An objective of the present invention is to provide a self-assembled polymer micelle-type ornithine donor, which has high bioavailability, low toxicity, and high therapeutic effectiveness, even when provided by oral administration. Another objective of the present invention is to provide a self-assembled polymer micelle-type ornithine donor which is effective in preventing or treating hepatic disorders. In order to achieve the above objectives, an acyl group is introduced into the primary amino group in the side chain of an ornithine unit in the poly(ornithine) segment of poly(ethylene glycol)-b-poly(ornithine), which spontaneously forms polymer micelles without polyion complex formation.
To stably support a user before and after posture transition between a standing position and a sitting position by suppressing forward and backward movement of a position of the center of gravity of a user without power supply with a simple configuration. A stable support mechanism includes a base, a support structure mounted on the base, the support structure being configured to be capable of translational movement along a first axis in a plane horizontal to the base, the support structure being configured to be capable of changing a posture between a first position and a second position in a plane perpendicular to the base, and a link having a fixed length, one end of the link being connected to the base, the other end of the link being connected to the support structure, the link being configured to guide the support structure in a direction along the first axis along with changing the posture of the support structure.
Biomarkers for detecting cognitive dysfunction diseases and methods for detecting cognitive dysfunction diseases using the biomarkers are provided. A method for detecting cognitive dysfunction diseases comprising measuring one or more biomarkers for detecting cognitive dysfunction diseases selected from the following (a), (b), and (c) in a biological sample simultaneously or separately: (a) a biomarker for detecting cognitive dysfunction diseases consisting of an intact protein of apolipoprotein A1 comprising the amino acid sequence represented by SEQ ID NO:1 or a partial peptide thereof; (b) a biomarker for detecting cognitive dysfunction diseases consisting of an intact protein of transthyretin comprising the amino acid sequence represented by SEQ ID NO:2 or a partial peptide thereof; and (c) a biomarker for detecting cognitive dysfunction diseases consisting of an intact protein of complement C3 comprising the amino acid sequence represented by SEQ ID NO:3 or a partial peptide thereof.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
64.
FEATURE AMOUNT SELECTION DEVICE, FEATURE AMOUNT SELECTION METHOD, AND PROGRAM
A feature amount selection device includes a feature amount data acquisition unit that acquires feature amount data including a set of values of a plurality of feature amounts for a sample, for each of a plurality of the samples, a principal component analysis unit that performs, on the feature amount data, principal component analysis in a sample space that is a collection of the plurality of feature amounts of a set of values for each of the plurality of the samples of the feature amounts, and a feature amount selection unit that selects a feature amount from among the plurality of the feature amounts based on a result of the principal component analysis performed by the principal component analysis unit.
A method for reconstructing an interior CT image in which a region of interest in an object is irradiated with X-rays and an image of the region of interest in a cross section of the object is reconstructed, wherein the method includes: a projection data acquisition step in which a plurality of pieces of projection data are acquired for an occasion on which the region of interest of the object is irradiated with X-rays in a predetermined angular range in the circumferential direction of the object; and an image calculation step in which when matrices holding pixel information for an occasion on which X-rays pass through a cross section of the object in accordance with the irradiation angle serve as projection calculation matrices, a vector in which the plurality of pieces of projection data are arranged is denoted by b, a matrix in which a plurality of the projection calculation matrices corresponding to the projection data are arranged is denoted by A, and a vector in which the image values of the cross section of the object are arranged is denoted by x, Ax = b is solved under prior information C and an image of the region of interest is determined, said prior information C being the sum of the image values of an image of the cross section of the object.
A secure computation system comprising secure computation server apparatuses, each of which comprises: a discriminant share generation part that computes discriminant shares configured so that an index relating to an input corresponds to a specific value from shares representing the index relating to the input and possible combinations of index shares of an array; a combination configuration part that configures a combination of shares of an element in the array and the discriminant shares for all possible combinations of indices of the array; a shuffle part that shuffles the combinations; a reconstruction part that reconstructs the discriminant shares in the shuffled combinations; and a selection part that selects shares of an element in the array in the combinations where the reconstructed value is the specific value.
G06F 21/57 - Certifying or maintaining trusted computer platforms, e.g. secure boots or power-downs, version controls, system software checks, secure updates or assessing vulnerabilities
An image display device displays a stereoscopic image by using a parallax barrier method and includes a transmissive image display surface on which images of left-eye image data and right-eye image data are alternately displayed; an image forming unit including optical members having strip-shaped patterns with optical properties arranged on a surface located on a back surface side of the image display surface; and strip-shaped light sources arranged on an illumination arrangement surface, which is a surface located on a back surface side of the image forming unit, and configured to irradiate the image display surface with illumination light. A slit area of the parallax barrier method is formed by an image obtained by forming an image of the illumination light from the strip-shaped light sources on the back surface side of the image display surface by using the optical members of the image forming unit.
H04N 13/312 - Image reproducers for viewing without the aid of special glasses, i.e. using autostereoscopic displays using parallax barriers the parallax barriers being placed behind the display panel, e.g. between backlight and spatial light modulator [SLM]
H04N 13/305 - Image reproducers for viewing without the aid of special glasses, i.e. using autostereoscopic displays using lenticular lenses, e.g. arrangements of cylindrical lenses
H04N 13/315 - Image reproducers for viewing without the aid of special glasses, i.e. using autostereoscopic displays using parallax barriers the parallax barriers being time-variant
68.
GENE INDUCING DIFFERENTIATION INTO FAST MUSCLE FIBERS, COMPOSITION FOR INDUCING DIFFERENTIATION INTO FAST MUSCLE FIBERS, METHOD FOR INDUCING DIFFERENTIATION INTO FAST MUSCLE FIBERS, COMPOSITION FOR INHIBITING DIFFERENTIATION INTO FAST MUSCLE FIBERS, METHOD FOR INHIBITING DIFFERENTIATION INTO FAST MUSCLE FIBERS, METHOD FOR PRODUCING MUSCLE TISSUE AND METHOD FOR PRODUCING EDIBLE MEAT
Provided are: a gene inducing differentiation into fast muscle fibers, said gene being capable of increasing or suppressing the ratio of fast muscle fibers in a muscle tissue and preventing or restoring muscle weakness caused by, for example, aging, injuries or diseases, etc.; a composition for inducing differentiation into fast muscle fibers; a method for inducing differentiation into fast muscle fibers; a method for producing a muscle tissue; and a method for producing an edible meat. A gene inducing differentiation into fast muscle fibers, said gene including a gene encoding a fast muscle fiber differentiation inducing factor comprising any of proteins MafA, MafB and c-Maf; and a composition for inducing differentiation into fast muscle fibers, a method for inducing differentiation into fast muscle fibers, a composition for inhibiting differentiation into fast muscle fibers, a method for inhibiting differentiation into fast muscle fibers, a method for producing a muscle tissue and a method for producing an edible meat, each mainly using the aforesaid gene.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
The purpose of the present invention is to provide a volatile material monitoring system that can accurately acquire the concentration of a volatile material, e.g., ethanol, in an incubator and thereby enable suitable management of the influence exercised by the volatile material on the health of a pediatric patient. The volatile material monitoring system comprises: one or a plurality of sensors (14a, 14b, 14c) disposed in an incubator (1) comprising a housing compartment (101) having a temperature- and humidity-regulatable interior in order to house a pediatric patient (X), wherein the sensor or sensors detect the concentration of a volatile material used due to medical intervention on a pediatric patient (X) in the housing compartment (101); and an estimation unit (161) that estimates, on the basis of the volatile matter concentration detected by the sensors (14a, 14b, 14c), the volatile matter blood concentration in the blood of the pediatric patient (X).
The present invention removes volatile substances from air in an incubator. A purification device (120) includes: an air intake part (121b) for taking in air; a suction part (125) for sucking the air; a second removal part (126) for removing volatile substances, which are substances used in medical intervention on an infant patient, from the air sucked by the suction part (125); and an exhaust part (122b) for exhausting the air from which the volatile substances have been removed by the second removal part (126).
The purpose of the present invention is to avoid the accidental exposure of an infant patient in an infant incubator to a volatile substance. This infant incubator (3) is provided with: a housing chamber (101) in which an infant patient (X) can be housed; and a removal section (134) for removing a volatile substance from air in the housing chamber (101).
F24F 7/003 - Ventilation in combination with air cleaning
F24F 8/158 - Treatment, e.g. purification, of air supplied to human living or working spaces otherwise than by heating, cooling, humidifying or drying by separation, e.g. by filtering by chemical means using active carbon
72.
VOLATILE SUBSTANCE REMOVAL APPARATUS AND VOLATILE SUBSTANCE REMOVAL METHOD
Provided is a volatile substance removal apparatus capable of sufficiently removing volatile substances such as ethanol floating around a child patient in an incubator. The volatile substance removal apparatus (110, 210, 110A) comprises: a suction unit (115) for suctioning air inside a storage chamber (101) from an intake unit (111c); a removal unit (114, 116) for removing volatile substances contained in the air; an exhaust unit (111d) for exhausting the air from which the volatile substances have been removed by the removal unit (114, 116); and a guide unit (112, 212) for guiding air to the intake unit (111c).
[Object] Provided is a method of producing a nerve fascicle including efficiently extending axons of neural cells.
[Object] Provided is a method of producing a nerve fascicle including efficiently extending axons of neural cells.
[Solution] Neural cells are cultivated in the presence of feeder cells including at least one type of cells selected from the group consisting of vascular component cells, perivascular cells, and oligodendrocytes.
An imaging lighting instrument for an operation is disposed in a space between an operator's head and a patient, thereby configuring a multi-viewpoint video capturing device for a surgical operation in which blocking of a light by the operator's head or body and appearance of the head in a video are avoided. The imaging lighting instrument includes a plurality of cameras and a plurality of lights attached to a hollow ring-shaped or arc-shaped housing made of a wire member of a finite length, which is devised so as not to interfere with the visual field or work of the operator. Furthermore, the multi-viewpoint video capturing device is configured to have a function of estimating the context of the plurality of cameras and make it possible to perform operation support/recording of a direct-view surgical operation by using a multi-viewpoint video by adding a video information processing function for selecting a camera video in which an operators' hand or surgical instruments less appear in an image.
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
A rocking device includes: a seat which supports a body of a user; a motor which rotates a rotation shaft in a first rotation direction and in a second rotation direction that is a rotation direction opposite to the first rotation direction, and thereby supplies motive power for rocking the seat via a gear attached to the rotation shaft; and a controller which controls rocking of the seat via the motor. The seat is configured to make a first motion of moving in a first movement direction, in accordance with rotation of the rotation shaft in the first rotation direction, and make a second motion of moving in a second movement direction, in accordance with rotation of the rotation shaft in the second rotation direction. The controller is configured to control rocking of the seat such that a prescribed stopped period is provided between the first motion and second motion.
An information processing apparatus acquires an image; generates a shielding image in which a part of an area included in an area of the acquired image has been shielded; calculates, by inputting the image to a first model that has been trained, first likelihood of the target object included in the image; calculates, by inputting the shielding image to a second model that calculates an approximation value of likelihood of the target object included in the image when the image is input, second likelihood corresponding to the approximation value of the likelihood of the target object included in the shielding image; specifies, based on the first likelihood and the second likelihood, an area that affects discrimination of the class and that is included in the area of the image; and displays the specified area that affects discrimination of the class.
G06V 10/36 - Applying a local operator, i.e. means to operate on image points situated in the vicinity of a given pointNon-linear local filtering operations, e.g. median filtering
G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (Japan)
UNIVERSITY OF TSUKUBA (Japan)
Inventor
Higashi Taishi
Motoyama Keiichi
Onodera Risako
Matsumoto Yoshitaka
Abstract
The purpose of the present invention is to provide a novel compound which can serve as a component of a boron pharmaceutical agent. The present application provides a boron-containing modified polyrotaxane comprising a plurality of cyclodextrin molecules, a single straight-chain molecule passing through the openings in the plurality of cyclodextrin molecules in a skewer-like manner, and a blocking group which is provided at both ends of the single straight-chain molecule and prevents the cyclodextrin molecules and the straight-chain molecule from separating, wherein at least some of the cyclodextrin molecules bind, via a linker, to boronic acid or a monovalent group derived therefrom.
This image processing device emits light from a light source onto an examined eye through an optical system of a first numerical aperture, and acquires information indicating interference light obtained by detecting interference light between signal light, in which light returning from the examined eye owing to the light emitted thereon is transmitted through an optical system of a second numerical aperture, and reference light, which is a division of light from the light source (S200). A first process (S202) is performed for projecting information indicating the interference light to a four-dimensional frequency aperture that is on a four-dimensional space of the light source frequency and the frequency of light from the examined eye owing to the signal light, and is formed by the optical system of the first numerical aperture and the optical system of the second numerical aperture. A second process (S204) is performed for projecting the projected information to a three-dimensional space.
A61B 3/10 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions
G01N 21/17 - Systems in which incident light is modified in accordance with the properties of the material investigated
80.
METHOD FOR TREATING PATIENT HAVING UNDERGONE PRE-TRANSPLANTATION PROCESS INVOLVED IN HEMATOPOIETIC STEM CELL TRANSPLANTATION, AND COMPOSITION FOR USE IN SAID METHOD
The present disclosure provides: a method for treating a patient who has undergone a pre-transplantation process involved in hematopoietic stem cell transplantation; and a composition for use in said method. The composition according to the present disclosure contains bone-marrow common progenitor cells.
A stage of sleep is easily estimated. A sleep estimation device includes a first acquisition unit configured to acquire blood flow data, a generation unit configured to generate a frequency spectrum of the blood flow data by performing frequency analysis processing on the blood flow data, and a first determination unit configured to determine a stage of sleep of a subject based on the frequency spectrum.
Provided is a robustness verification device comprising: a similar image identification means that uses a degree of similarity between feature amounts obtained by a feature amount extractor to identify a similar image having a predetermined order position in the degree of similarity to the input image in a candidate image group; an order position count means that counts the order position of the similar image with respect to the input image in the candidate image group when adversarial perturbation is applied to the image; a order position calculation means that calculates the order position of the similar image with respect to the input image in the candidate image group when the adversarial perturbation is not applied to the image; and an order position verification means that verifies whether the order position of the similar image counted by the order position count means is within a prescribed range containing the order position of the similar image calculated by the order position calculation means.
G06F 21/57 - Certifying or maintaining trusted computer platforms, e.g. secure boots or power-downs, version controls, system software checks, secure updates or assessing vulnerabilities
83.
LEARNING DEVICE, LEARNING METHOD, AND RECORDING MEDIUM
This learning device comprises a learning means for performing learning of a feature amount extractor f such that the upper limit and the lower limit of a distance, obtained when the feature amount extractor is used, in a feature space between images become close to the distance.
A paramylon-based resin having a weight-average molecular weight of paramylon in a range of 70000 to 140000, and formed by substituting hydrogen atoms of hydroxy groups of a paramylon with a long-chain component being a linear saturated aliphatic acyl group having 14 or more carbon atoms and a short-chain component being an acyl group (acetyl group or/and propionyl group) having 2 or 3 carbon atoms, wherein a degree of substitution with the long-chain component (DSLo) and a degree of substitution with the short-chain component (DSSh) satisfy the following conditional expressions (1) and (2), Izod impact strength is 5.0 kJ/m2 or more, and an MFR (melt flow rate at 210° C. and under a load of 5 kg) is 2 g/10 min or more. To provide a paramylon-based resin excellent in mechanical characteristics and thermoplasticity. 2.2≤DSLo+DSSh≤2.8 (1) 5≤DSSh/DSLo≤25 (2)
C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
85.
SCANNING IMAGING DEVICE, INFORMATION PROCESSING DEVICE, METHOD FOR CONTROLLING SCANNING IMAGING DEVICE, METHOD FOR CONTROLLING INFORMATION PROCESSING DEVICE, INFORMATION PROCESSING METHOD, PROGRAM, AND RECORDING MEDIUM
An ophthalmic examination device 1 according to an embodiment is a scanning imaging device for imaging a sample using optical scanning. The ophthalmic examination device 1 acquires a data set by redundantly collecting data on a sample by the optical scanning using an optical scanner 44, an OCT unit 100, and a control section 210. An image data construction section 220 generates an image set on the basis of the acquired data set. An image selection section 225 selects a plurality of images from the generated image set. An image data processing section 231 executes relative positional adjustment of this image set by applying, to this image set, a plurality of registrations respectively based on the selected plurality of images.
A first estimation unit (331) estimates command information per first unit of time using a first trained model (321). A second estimation unit (332) estimates, using a second trained model (322), the command information per second unit of time shorter than the first unit of time, from information corresponding to the command information derived by the first trained model (321). An operation control unit (333) operates a control target device (10B) using the command information estimated by the second estimation unit (332).
NATIONAL AGRICULTURE AND FOOD RESEARCH ORGANIZATION (Japan)
JAPAN INTERNATIONAL RESEARCH CENTER FOR AGRICULTURAL SCIENCES (Japan)
UNIVERSITY OF TSUKUBA (Japan)
KAKE EDUCATIONAL INSTITUTION (Japan)
Inventor
Hara Takashi
Ishiguro Koji
Otsuka Shiori
Satoh Rie
Matsui Katsuhiro
Suzuki Tatsuro
Yasui Yasuo
Osawa Ryo
Kondo Yasuto
Okamoto Kaoru
Teshima Reiko
Maruyama Kyonoshin
Abstract
The present invention addresses the problem of providing a Fagopyrum plant having reduced allergen reactivity. In the Fagopyrum plant, the Fag e 2 gene is mutated, and the Fag e 2 protein is deleted. If there is a stop codon mutation in the translation region, it is preferable to have a stop codon mutation so as not to generate a mutant protein having a reduced molecular weight.
The present invention relates to a pharmaceutical composition for blood cell recovery after allogeneic cord blood transplant, the pharmaceutical composition containing romiplostim as an active ingredient. The pharmaceutical composition is characterized by being administered starting the day after the transplant. The present invention also relates to a method for treating an allogeneic cord blood transplant recipient using the pharmaceutical composition.
NIPPON TELEGRAPH AND TELEPHONE CORPORATION (Japan)
UNIVERSITY OF TSUKUBA (Japan)
Inventor
Nagata, Masaaki
Wei, Yizhen
Utsuro, Takehito
Abstract
Provided is an estimation device equipped with: an input unit for inputting an expanded word correspondence for original text and translated text, and a translation quality tag for said original text and said translated text; and an editing tag estimation unit for estimating an editing tag on the basis of the expanded word correspondence and the translation quality tag.
Provided is a pavement structure which has good workability and durability and can sustainably draw electricity from an environment such as a facility infrastructure. A pavement structure (1) in which a roadbed layer (2) and a road surface layer (3) supported by the roadbed layer (2) are installed, wherein the roadbed layer (2) comprises a layered part (80) formed by stacking unit structures (81) having a void, and a device part (10) shaped like a box. The device part (10) has a tertiary battery part (30) that generates electricity from variations in electrode temperature and/or a thermoelectric conversion cell part (20) that generates electricity from the difference in temperature between electrodes.
22 in the poly(cysteine) being protected by a hydrophobic alkylcarbonyl, hydrophobic alkylthio, or the like. Also disclosed are self-organizing nanoparticles of such a copolymer and the use of said self-organizing nanoparticles. The copolymer or self-organizing nanoparticles have low toxicity and exhibit efficacy in, e.g., the prevention or treatment of cancer, acute liver injury, inflammatory liver disease, septicemia, or ulcerative colitis through oral administration.
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
A61K 38/02 - Peptides of undefined number of amino acidsDerivatives thereof
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
The present invention improves the quality of sleep. According to the present invention, a control device comprises a determination unit that determines the sleep stage of a subject on the basis of bioinformation for the subject and a control unit that controls a sleep induction device that comprises a beat generation unit that generates binaural beats. The control unit makes the beat generation unit generate binaural beats that have a frequency of less than 1.0 Hz at least during the sleep stages of the subject.
A61M 21/02 - Other devices or methods to cause a change in the state of consciousnessDevices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis for inducing sleep or relaxation, e.g. by direct nerve stimulation, hypnosis, analgesia
93.
ELECTRON SPIN RESONANCE DEVICE AND DETERIORATION EVALUATION METHOD
This electron spin resonance device comprises a hollow resonator having a microwave oscillator, a magnet, a modulation coil, and an opening. Microwaves generated by the microwave oscillator resonate in the hollow resonator and are emitted from the opening toward an object being measured that is positioned outside of the opening. The magnet applies a magnetic field to an irradiated surface at which the object being measured is irradiated with the microwaves. The modulation coil modulates either the strength of the magnetic field applied to the irradiated surface at which the object being measured is irradiated with the microwaves, or the frequency of the microwaves.
G01N 24/10 - Investigating or analysing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using electron paramagnetic resonance
An object is to elucidate the immune response mechanism of IL-17-producing cells which causes a pathological condition such as psoriasis, and to provide an immune response suppressant for suppressing the immune response of IL-17-producing cells, a medicament for treating or preventing a disease or a pathological condition involving the immune response of an IL-17-producing cell, a method for inducing immune response in γδT cells, and a method for evaluating a medicament (candidate substance) and a method for producing IL-17 by use of the method. The present invention provides an immune response suppressant for an IL-17-producing cell, including a substance that inhibits the binding of CD96 to at least one protein selected from CD155 and CD111, a medicament including the immune response suppressant for an IL-17-producing cell, a method having a step (A) of culturing at least one of a γδT cell and a CD4-positive T cell together with IL-23, an anti-CD3 antibody capable of stimulating a TCR/CD3 complex and an anti-CD96 antibody capable of stimulating CD96, and a method for evaluating a medicament (candidate substance) and a method for producing IL-17, including a method having the step (A).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
Provided is an assistance device which can independently control assistance with knee bending/extending actions and assistance with upper body posture. The assistance device comprises a base, a first link fixed to the base, a second link rotatably linked to the first link, a third link rotatably linked to the second link, and an elastic connection part incorporated between the third link and a prescribed position on the first link or the base.
In the present invention, an anticancer drug/prodrug is used in a combination therapy with radiotherapy. In the chemical formula representing the same, the moiety in which R1 and R2 are bonded to an N atom results from the removal of an amino group or an imino group from an anticancer drug (selected from the group consisting of, e.g., gemcitabine, niraparib, crizotinib, dabrafenib, vemurafenib, entinostat, cobimetinib, palbociclib, and ribociclib) having the amino group or the imino group. Adverse effects from the effect of treating malignant tumors using radiotherapy are thereby reduced, or the effect of the treatment is enhanced.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 31/4406 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/4523 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
An image generation device includes a tomographic image acquisition unit configured to acquire an OCTA tomographic image that captures a distribution of a blood flow of an object, a light attenuation acquisition unit configured to acquire a light attenuation of measurement light emitted to the object in a direction in which the tomographic image is layered, and an image generation unit configured to generate a light attenuation-blood flow distribution chart indicating a distribution of the light attenuation based on the acquired OCTA tomographic image and the light attenuation.
A61B 3/12 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
A61B 3/10 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions
This medical imaging equipment has an illumination unit 11 for spot-illuminating the center of a surgical field of a surgery patient, a surgical field camera unit 12 for imaging the center of the range irradiated by the illumination unit 11, a casing 13 for covering the illumination unit 11 and the surgical field camera unit 12, and a pair of display units 14, 14 that can be viewed from both sides of the surgery patient.
In the present invention, an anticancer drug/prodrug is used in a combination therapy with radiotherapy. In the chemical formula representing the same, the moiety in which R1 and R2 are bonded to an N atom results from the removal of an amino group or an imino group from an anticancer drug (selected from the group consisting of, e.g., gemcitabine, niraparib, crizotinib, dabrafenib, vemurafenib, entinostat, cobimetinib, palbociclib, and ribociclib) having the amino group or the imino group. Adverse effects from the effect of treating malignant tumors using radiotherapy are thereby reduced, or the effect of the treatment is enhanced.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4406 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/4523 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
This SREBP-1 inhibitor has inhibitory activity against SREBP-1 and does not have inhibitory activity against SREBP-2, the SREBP-1 inhibitor containing, as an active ingredient, one or more compounds from among compounds represented by formulas (1) to (23). This pharmaceutical composition for treating hypertriglyceridemia contains the aforementioned SREBP-1 inhibitor and a pharmacologically acceptable carrier.
A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/4365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
C07D 209/88 - CarbazolesHydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
C07D 231/44 - Oxygen and nitrogen or sulfur and nitrogen atoms
C07D 333/38 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 491/22 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains four or more hetero rings
patents
